SUGI 29 Posters. Web Server



Similar documents
How to build ADaM from SDTM: A real case study

NEXT. Tools of the Participant Portal: Scientific Reports & Deliverables

StARScope: A Web-based SAS Prototype for Clinical Data Visualization

7.6 VULNERABILITY SCANNING SERVICE (VSS) (L ; C ) Satisfying the Service Requirements (L (c))

PharmaSUG Paper DG06

Bridging Statistical Analysis Plan and ADaM Datasets and Metadata for Submission

UNITED STATES DEPARTMENT OF EDUCATION OFFICE FOR CIVIL RIGHTS THE WANAMAKER BUILDING, SUITE PENN SQUARE EAST PHILADELPHIA, PA

Scatter Chart. Segmented Bar Chart. Overlay Chart

RARITAN VALLEY COMMUNITY COLLEGE ACADEMIC COURSE OUTLINE MATH 111H STATISTICS II HONORS

SAS CLINICAL TRAINING

Introduction Course in SPSS - Evening 1

Scatter Plots with Error Bars

4 Other useful features on the course web page. 5 Accessing SAS

FTS NETWORX Enterprise TQC-JTB

Systat: Statistical Visualization Software

MAT 282 STATISTICS 3 cr. (3-0) (online sections)

IVA Funds New IRA Account Application

Schneps, Leila; Colmez, Coralie. Math on Trial : How Numbers Get Used and Abused in the Courtroom. New York, NY, USA: Basic Books, p i.

SAS BI Dashboard 4.4. User's Guide Second Edition. SAS Documentation

SAS IT Resource Management 3.2

Paper PO03. A Case of Online Data Processing and Statistical Analysis via SAS/IntrNet. Sijian Zhang University of Alabama at Birmingham

SAS Add in to MS Office A Tutorial Angela Hall, Zencos Consulting, Cary, NC

P: E: W:

TEMPLATE DATA MANAGEMENT PLAN

Monitoring Clinical Trials with a SAS Risk-Based Approach

SAS Information Delivery Portal: Organize your Organization's Reporting

Can SAS Enterprise Guide do all of that, with no programming required? Yes, it can.

Directions for using SPSS

Introduction to SAS Business Intelligence/Enterprise Guide Alex Dmitrienko, Ph.D., Eli Lilly and Company, Indianapolis, IN

Guide to Operating SAS IT Resource Management 3.5 without a Middle Tier

PharmaSUG Paper HS01. CDASH Standards for Medical Device Trials: CRF Analysis. Parag Shiralkar eclinical Solutions, a Division of Eliassen Group

Univariate Regression

Payer-Industry Partnerships in Emerging Markets: Best Practices for Successful Market Access of New Pharmaceuticals STUDY EXTRACT: CHINA P3696

8. Comparing Means Using One Way ANOVA

ABSORBENCY OF PAPER TOWELS

IBM SPSS Statistics 20 Part 1: Descriptive Statistics

Contents. Financial Analysis Report

5.2.2 Voice Over Internet Protocol Transport Services (VOIPTS) (L ; C.2.7.8)

From The Little SAS Book, Fifth Edition. Full book available for purchase here.

Kaplan-Meier Survival Analysis 1

UM Discrete Class D High Power Audio Amplifier. Document information

PharmaSUG Paper DV05

USE OF ARIMA TIME SERIES AND REGRESSORS TO FORECAST THE SALE OF ELECTRICITY

Licensed Functionality: Remote Monitoring

9.2 User s Guide SAS/STAT. Introduction. (Book Excerpt) SAS Documentation

Multiple Linear Regression

Deutsche Bank Paper Invoice Submission and Compliance Requirements Manual (PO and Non PO) India Region

ABSTRACT INTRODUCTION PATIENT PROFILES SESUG Paper PH-07

SAS. 9.4 Guide to Software Updates. SAS Documentation

SAS Enterprise Guide in Pharmaceutical Applications: Automated Analysis and Reporting Alex Dmitrienko, Ph.D., Eli Lilly and Company, Indianapolis, IN

SAS Add-In 2.1 for Microsoft Office: Getting Started with Data Analysis

SAS. 9.3 Guide to Software Updates. SAS Documentation

NCSS Statistical Software Principal Components Regression. In ordinary least squares, the regression coefficients are estimated using the formula ( )

WebFOCUS RStat. RStat. Predict the Future and Make Effective Decisions Today. WebFOCUS RStat

TAFE TEACHERS AND RELATED EMPLOYEES ENTERPRISE AGREEMENT Statements of duties for proposed new roles

MEASURES OF LOCATION AND SPREAD

Hands-On Workshops HW003

Graphical Analyses of Clinical Trial Safety Data

T Analyst User Guide 1

2015 Workshops for Professors

Capital Investment in Health Report of the Department of Health. Overview and Priorities

1. What is the critical value for this 95% confidence interval? CV = z.025 = invnorm(0.025) = 1.96

SAS Software to Fit the Generalized Linear Model

Bowerman, O'Connell, Aitken Schermer, & Adcock, Business Statistics in Practice, Canadian edition

UnitedHealthcare India Claims Document Submission-Self Service Tool

ILLUMINATE ASSESSMENT REPORTS REFERENCE GUIDE

Enhance efficiency and productivity of Clinical Trial with Timetrack. Bing Hu, Clinovo, Sunnyvale, CA Marc Desgrousilliers, Clinovo, Sunnyvale, CA

SAS. Cloud. Account Administrator s Guide. SAS Documentation

2. Filling Data Gaps, Data validation & Descriptive Statistics

Visualizing Clinical Trial Data Matt Becker, SAS Institute

Copyright 2012, SAS Institute Inc. All rights reserved. VISUALIZATION OF STANDARD TLFS FOR CLINICAL TRIAL DATA ANALYSIS

STAT355 - Probability & Statistics

SQL Reporting Services: A Peek at the Power & Potential

Using The Paessler PRTG Traffic Grapher In a Cisco Wide Area Application Services Proof of Concept

PharmaSUG 2015 Paper SS10-SAS

Integrating SAS with JMP to Build an Interactive Application

PH 7525 Introduction to Data & Statistical Packages Course Reference #: Spring 2011

3.2 Program Management (L ; C.7; G.1.3)

Style Guide for the Applied Dissertation

SPSS Tests for Versions 9 to 13

Web Server XX Configuration Guide

Switching from PC SAS to SAS Enterprise Guide Zhengxin (Cindy) Yang, inventiv Health Clinical, Princeton, NJ

Market Pricing Override

Chapter 27 Using Predictor Variables. Chapter Table of Contents

CC03 PRODUCING SIMPLE AND QUICK GRAPHS WITH PROC GPLOT

Optimally Scheduling Resource Constraint Project Using SAS/OR Jeff Cai, Amgen Inc., Thousand Oaks, CA

An Introduction to SPSS. Workshop Session conducted by: Dr. Cyndi Garvan Grace-Anne Jackman

Lean Six Sigma Black Belt-EngineRoom

Metadata and ADaM.

Transcription:

Paper 151-29 Clinical Trial Online Running SAS. on the Web without SAS/IntrNet. Quan Ren ABSTRACT During clinical trial, it is very important for the project management to have the most recent updated clinical trial information. The best solution is dynamic access to clinical trial data: dynamic data management and dynamic data analysis. SAS System almost became a standard programming language in clinical data analysis. With the development in Internet, people have been exploring every technical possibility to use SAS System to manage and analyze clinical trial data dynamically through Internet. SAS/IntrNet software has provided an option to use SAS System through Internet. However, there is an additional cost. This paper will present another way to use SAS System through Internet without SAS/IntrNet. An experimental example - Clinical Trial Online will be presented. Through Clinical Trial Online, the following technique will be demonstrated: 1. Remote data entry, data browsing and data editing through Internet. 2. Running SAS programs remotely and bringing the results back to users' Internet browser. 3. Building menu driven system to give users the option to analyze the data interactively through Internet. INTRODUCTION Clinical Trial Online is a Web interactive, point-click menu driven system. Anyone can use it. Programming is not needed from the end users. SAS system is used as database system. In reality, other DBMS can be easily adapted as database systems. From user's point of view, only a Web browser is needed. From system administrator's point of view, only a regular Web Server with CGI broker and a regular SAS system need to be set up. Most important, SAS/IntrNet is not necessary. Every time when a user clicks on a Web page and sends a request to Web Server, Web Server takes the request and communicates it through CGI to SAS System; SAS System process the request and sends the results back to Web Server, and Web Server sends the results back to the user. Web Server User request Web Server communicates the request to SAS System Results back to user SAS process the request and send results back to Web Server SAS System User/Browser The System has the following main sections: 1. Project Status 2. Study Design 3. Database Management 4. Statistical Analysis 5. Research Report 6. Reference resources SYSTEM HIGHLIGHTS 1. PROJECT STATUS Tracking the current database status including data verification/validation,. 2. STUDY DESIGN Access study design documents (e.g. protocol, ). 1

3. DATA MANAGEMENT Through Data Management System, you can access CRF form, enter, edit and review data through Internet. I. Data Entry II. Data Edit III. Data Review 4. STATISTICAL ANALYSIS Statistical analysis has Pre-defined Analysis and Interactive Analysis/Online Analysis two sections: A. Pre-defined Analysis Pre-defined Analysis gives a user the option to run an existing SAS program remotely through Internet and bring the result back to the user/web browser. B. Interactive Analysis/Online Analysis Interactive Analysis is a menu driven system; users can define their own analyses by just point-clicking the menus through Internet. It is featured with Descriptive Analysis, Safety Analysis (Prior/Concurrent Medication, Vital Sign, Adverse Events and Laboratory Test), ANOVA Analysis, Pairwise Comparison, Survival Analysis and Graphic Analysis. It can also generate output files in PDF format. I. Descriptive Analysis Descriptive Analysis System is designed for basic statistical analysis, it can be used for summary analysis. For example: 1. Demographic Information Summary 2. Study Termination Reason Summary, 3. etc. II. Incidence Summary Incidence Summary System includes: Prior/Concurrent Medication Use Analysis, Prior/Concurrent Surgical Procedure Analysis, Medical History Analysis and other Incidence analysis. It can not only summarize the incidence but also compare the equality of proportions across different groups using CMH test. III. Adverse Events Analysis It can not only summarize the incidence of Adverse Events but also compare the equality of proportions across different groups using CMH test. 1. Summary of Adverse Event Report 2. Incidence of Adverse Events 3. Incidence of Adverse Events by Body System 4. Incidence of Adverse Events by Severity 5. Incidence of Adverse Events by Attribution 6. Incidence of Serious Adverse Events 7. Incidence of Adverse Events Causing Withdrawal 8. Incidence of Adverse Events by Subgroup 9. Frequency of Adverse Events IV. Vital Sign Analysis Vital sign information can be summarized through Descriptive Analysis System. V. Laboratory Test Analysis 1. Summary of Laboratory Test 2. Summary of Laboratory Test Change 3. Lab Test Change Relative to Normal Range 4. Laboratory Test Distribution Among Ranges 5. Laboratory Test Shift Plot VI. ANOVA Analysis ANOVA p-values can be calculated using GLM model. VII. Pairwise Comparison Analysis Pairwise comparison p-values can be calculated using GLM Model. VIII. Survival Analysis Proportion of survival can be estimated and the results will be presented in graphic format. IX. Graphic Analysis Data can be summarized and visually displayed using plot, joint line, smooth line, regression line, pie, bar or block. Data used to generate the graphs can also be displayed on the graphs for review. 2

5. RESEARCH REPORT Access study research reports. 6. REFERENCE RESOURCES Access study reference information. A SAMPLE OF INTERACTIVE / ONLINE ANALYSIS OUTPUTS Descriptive analysis can be used to calculate the following statistics: N, Percent, Mean, Standard Deviation, Standard Error, Variance, C.V., Median, Q1, Q3, Qrange( Q3 Q1), P5, P95, Minimum, Maximum, Range,. Subgroup Variables Descriptive Analysis Across variables XX XX XXX XXX XX XXX XXX XXXX XXXX XXXX XXX XXXX XXX N=XX N=XX N=XX N=XX N=XX N=XX N xxx xxx xxx xxx xxx xxx Mean xxx xxx xxx xxx xxx xxx Std xxx xxx xxx xxx xxx xxx Var xxx xxx xxx xxx xxx xxx C.V. xxx xxx xxx xxx xxx xxx Min xxx xxx xxx xxx xxx xxx Max xxx xxx xxx xxx xxx xxx N xxx xxx xxx xxx xxx xxx Mean xxx xxx xxx xxx xxx xxx Std xxx xxx xxx xxx xxx xxx Var xxx xxx xxx xxx xxx xxx C.V. xxx xxx xxx xxx xxx xxx Min xxx xxx xxx xxx xxx xxx Max xxx xxx xxx xxx xxx xxx xxxxxxxx xxx xxx xxx xxx xxx xxx xxxxxx xxx xxx xxx xxx xxx xxx Group variables Analysis variables Subgroup variables Summary of Prior/Concurrent Medication Use (1) (Summary of Prior/Concurrent Surgical Procedure) Group/Treatment variable Item variable N=XXX N=XXX N=XXX N=XXX N % N % N % N % ***Total*** xx xx.x xx xx.x xx xx.x xx xx.x xxxxxxxx xx xx.x xxxxx xx xx.x xxxxxxxxxxxxxxx xx xx.x xxxxxxxxxxxxxx xx xx.x xxxxxxxxxx xx xx.x xxxxxxxxxxxxxx xx xx.x xxxxxxx xx xx.x xxxxxxxxxxx xx xx.x xxxxxxxxxxx xx xx.x 3

Summary of Prior/Concurrent Medication Use (2) (Summary of Prior/Concurrent Surgical Procedure) N=XXX N=XXX N=XXX N % N % N % p-value ***Total*** xx xx.x xx xx.x xx xx.x x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx Summary of Adverse Events Report N=XXX N=XXX N=XXX N % N % N % Subject Reporting AE xx xx.x xx xx.x xx xx.x Subject Reporting AE by Attribution - Possible xx xx.x xx xx.x xx xx.x Subject Reporting AE by Attribution - Probable xx xx.x xx xx.x xx xx.x Subject Reporting AE by Attribution - Definite xx xx.x xx xx.x xx xx.x Subject Reporting AE by Severity - Mild xx xx.x xx xx.x xx xx.x Subject Reporting AE by Severity - Moderate xx xx.x xx xx.x xx xx.x Subject Reporting AE by Severity - Severe xx xx.x xx xx.x xx xx.x Subject Reporting Serious AE - Non-fatal xx xx.x xx xx.x xx xx.x Subject Withdrawn due to AE xx xx.x xx xx.x xx xx.x Number of Deaths xx xx.x xx xx.x xx xx.x Incidence of Adverse Events (1) (Incidence of Serious Adverse Events) (Incidence of Adverse Events Causing Withdrawal) Adverse Events N=XXX N=XXX N=XXX N=XXX N % N % N % N % ***Total*** xx xx.x xx xx.x xx xx.x xx xx.x xxxx xx xx.x xxx xx xx.x xx xx.x xx xx xx.x xx xx.x xx xx.x xxxxxxxxxx xx xx.x xxxxx xx xx.x xx xx.x 4

Incidence of Adverse Events (2) (Incidence of Serious Adverse Events) (Incidence of Adverse Events Causing Withdrawal) N=XXX N=XXX N=XXX N % N % N % p-value ***Total*** xx xx.x xx xx.x xx xx.x x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx x.xxx Incidence of Adverse Events by Body System (1) (Incidence of Serious Adverse Events by Body System) (Incidence of AE Causing Withdrawal by Body System) Body System/ Adverse Events xxxxxxxxxx xxxx N=XXX N=XXX N=XXX N % N % N % ***Total*** xx xx.x xx xx.x xx xx.x ***Total*** xx xx.x xx xx.x xx xx.x Incidence of Adverse Events by Body System (2) (Incidence of Serious Adverse Events by Body System) (Incidence of AE Causing Withdrawal by Body System) Body System/ Adverse Events xxxxxx xxxxxxx N=XXX N=XXX N=XXX p-value N % N % N % ***Total*** xx xx.x xx xx.x xx xx.x x.xxx xxxx x.xxx xx x.xxx xxxx x.xxx xx x.xxx ***Total*** xx xx.x xx xx.x xx xx.x x.xxx x x.xxx xxxxx x.xxx xxx x.xxx xx x.xxx 5

Incidence of Adverse Events by Severity Body System/ Adverse Events xxxxxxxxxx xxxx XX N=XXX Mild Moderate Severe N % N % N % ***Total*** xx xx.x xx xx.x xx xx.x ***Total*** xx xx.x xx xx.x xx xx.x Incidence of Adverse Events by Attribution Body System/ Adverse Events xxxxxxxxxx xxxx XX N=XXX Possible Probable Definite N % N % N % ***Total*** xx xx.x xx xx.x xx xx.x ***Total*** xx xx.x xx xx.x xx xx.x Lab Test Change Relative to Normal Range LAB TEST xxxxxxx xxxx xxxxxxx X XXXX XX N % N % N % Decrease xx xx.x xx xx.x xx xx.x Increase xx xx.x xx xx.x xx xx.x No change xx xx.x xx xx.x xx xx.x Total xx xx.x xx xx.x xx xx.x Decrease xx xx.x xx xx.x xx xx.x Increase xx xx.x xx xx.x xx xx.x No change xx xx.x xx xx.x xx xx.x Total xx xx.x xx xx.x xx xx.x Decrease xx xx.x xx xx.x xx xx.x Increase xx xx.x xx xx.x xx xx.x No change xx xx.x xx xx.x xx xx.x Total xx xx.x xx xx.x xx xx.x 6

Lab Test Distribution Among Ranges LAB TEST = X X H L N TOTAL H L N TOTAL (N) (N) H x x x x H x x x x L x x x x L x x x x N x x x x N x x x x TOTAL x x x x TOTAL x x x x <PRE-TIME> POSTTIME <PRE-TIME> POSTTIME X H L N TOTAL H L N TOTAL (%) (%) H x x x x H x x x x L x x x x L x x x x N x x x x N x x x x TOTAL x x x x TOTAL x x x x <PRE-TIME> POSTTIME <PRE-TIME> POSTTIME 7

LAB Shift Plot LAB TEST=, TREATMENT=XXXX (N=XXX) 100 80 Post-time 60 40 20 0 0 20 40 60 80 100 Pre-time Decrease Increase No change Survival Analysis Plot of Survival 1 0.8 0.6 Survival 0.4 0.2 0 0 1 2 3 Time 4 group1 group2 group3 8

Survival Analysis Plot of Failure 1 0.8 Failure 0.6 0.4 0.2 0 0 1 2 3 4 Time group1 group2 group3 ANOVA Analysis Group variables xxxxxxxx xxxxxxx xxxxxx xxxxxxx xx xxxxxx x.xxx x.xxx x.xxx x.xxx xxxxxxx x.xxx x.xxx x.xxx x.xxx xxxxxx x.xxx x.xxx x.xxx x.xxx xxxxxxx x.xxx x.xxx x.xxx x.xxx Analysis Variables P-values Pairwise Comparisons Pairwise Comparisons xxxxxxxx xxxxx xxxx xxxxx vs vs vs vs xxxxxxx xxxxxxx xxxxxx xxxxx xx xxxxxx x.xxx x.xxx x.xxx x.xxx xxxxxxx x.xxx x.xxx x.xxx x.xxx xxxxxx x.xxx x.xxx x.xxx x.xxx xxxxxxx x.xxx x.xxx x.xxx x.xxx Analysis Variables P-values 9

A SAMPLE OF SYSTEM INTERNET PAGE Main page which has links to different features. Data management page that can link to CRF form, remote data entry, data editing and browsing. 10

An example CRF form through which data can be entered into remote central database. An example of data browse/review page 11

Statistical analysis main page that can link to Pre-defined Analysis and Interactive/Online Analysis. An example of Pre-defined Analysis page: each link can run an existing SAS program remotely. 12

An example of Pre-define analysis output. Interactive/Online Analysis main page can link to a lot of different analyses through internet. Through this online menu driven system, users can define their own analyses. 13

An example of Adverse Events Analysis menu through Interactive/Online Analysis System. An example of Interactive/Online analysis output. 14

An example of Interactive/Online survival analysis output. CONCLUSIONS This paper highlighted the Clinical Trial Online system; There are still a lot of other features not mentioned. This system is still in the experimental stage. A lot of other data management or analysis methods can be easily incorporated. Moreover, it s very easy to be set up. TRADEMARKS SAS and SAS/IntrNet are registered trademarks of SAS Institute Inc. in the USA and other countries. indicates USA registration. Other brand and product names are registered trademark or trademarks of their respective companies. REFERENCES SAS Institute Inc. (1990), SAS Language: Reference, Version 6, First Edition, Cary, NC: SAS Institute Inc. CONTACT INFORMATION Your comments and questions are valued and encouraged. For detailed information, please contact the author at: Quan Ren 2005 Willow Oak Lane Cedar Knolls, NJ 07927 (973) 267-0160 E-mail: quanren@yahoo.com 15